JOINTSTEM

Phase 3Small molecule

RR-Bio

JOINTSTEM is one of 54 small molecule programs targeting Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthritisActive, not recruiting

OsteoarthritisActive, not recruiting

ArthritisPhase 2

Active, not recruiting

OsteoarthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

JOINTSTEM

RR-Bio

Phase 3

3 2

Cataflam

Novartis

Preclinical

—3

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 4

Catapres

Boehringer Ingelheim

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Lunesta

Akero Therapeutics

Preclinical

1 8

Naproxen Sodium

Bayer

Preclinical

1 9

Ansaid

PPharmacia and Upjohn

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Recruiting

Osteoarthritis

NCT04368806

Q4 2027

Phase 3Active, not recruiting

Clinical Trial

NCT04427930

Q4 2029

N/ANot yet recruiting

Arthroscopy

NCT04825730

Clinical

Trials by Indication[1]

Osteoarthritis3 trials

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

Completed·NNature Cell Co. Ltd.·Phase 2·NCT02674399·28 enrolled

A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis

Recruiting·NNature Cell Co. Ltd.·Phase 2/3·NCT04368806·140 enrolled

A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

Completed·RR-Bio·Phase 3·NCT03990805·260 enrolled

Arthroscopy2 trials

Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration

Unknown status·RR-Bio·N/A·NCT04821102·21 enrolled

Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy

Not yet recruiting·RR-Bio·N/A·NCT04825730·14 enrolled

Clinical Trial2 trials

Follow-up Study for Participants Jointstem Clinical Trial

Completed·RR-Bio·Phase 2·NCT03509025·11 enrolled

Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial

Active, not recruiting·RR-Bio·Phase 3·NCT04427930·129 enrolled

Arthritis1 trial

Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis

Completed·RR-Bio·Phase 2·NCT02658344·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for JOINTSTEM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JOINTSTEM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JOINTSTEM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — R-Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RR-Bio

JOINTSTEM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2029

Trials by Indication[1]

Osteoarthritis3 trials

Arthroscopy2 trials

Clinical Trial2 trials

Arthritis1 trial

References

Drug Info

Quick Facts

Related News